Technical analysis for Greenwich Lifesciences Inc. GLSI including support levels resistance levels and stop losses for GLSI ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Greenwich LifeSciences (GLSI – Research Report) ...

Greenwich LifeSciences (GLSI) announced an update on FLAMINGO-01 open label HLA data. Analysis of the open label data from FLAMINGO-01 has ...

Greenwich LifeSciences, Inc.'s main program, GLSI-100, faces challenges in proving its benefit over existing HER2-positive breast cancer treatments, with ongoing phase 3 trial results expected by ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01 ...

ThoughtFocus, Inc. ("ThoughtFocus" or the "Company"), a leading provider of digital services and technology-enabled operations specializing in the financial services industry, is proud to announce ...

StarCompliance ("Star"), the leading provider of employee compliance technology solutions, has released the key findings of their fourth annual Crypto & Compliance Survey 2024 which examines how ...

STAFFORD, Texas - Greenwich LifeSciences, Inc. (NASDAQ:GLSI), a clinical-stage biopharmaceutical company valued at $163 million, has announced the commencement of analysis on the open label HLA data ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...